vs
AdvanSix Inc.（ASIX）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是AdvanSix Inc.的1.5倍（$540.7M vs $359.9M），AdvanSix Inc.净利率更高（-0.8% vs -2.9%，领先2.1%），AdvanSix Inc.同比增速更快（9.4% vs -14.1%），AdvanSix Inc.自由现金流更多（$36.1M vs $36.0M），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs -2.3%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ASIX vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.5倍
$359.9M
营收增速更快
ASIX
高出23.5%
-14.1%
净利率更高
ASIX
高出2.1%
-2.9%
自由现金流更多
ASIX
多$173.0K
$36.0M
两年增速更快
ASIX
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $540.7M |
| 净利润 | $-2.8M | $-15.7M |
| 毛利率 | 7.6% | 37.5% |
| 营业利润率 | -0.7% | 1.0% |
| 净利率 | -0.8% | -2.9% |
| 营收同比 | 9.4% | -14.1% |
| 净利润同比 | -892.9% | 34.0% |
| 每股收益（稀释后） | $-0.11 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXICUI
| Q4 25 | $359.9M | $540.7M | ||
| Q3 25 | $374.5M | $537.0M | ||
| Q2 25 | $410.0M | $548.9M | ||
| Q1 25 | $377.8M | $604.7M | ||
| Q4 24 | $329.1M | $629.8M | ||
| Q3 24 | $398.2M | $589.1M | ||
| Q2 24 | $453.5M | $596.5M | ||
| Q1 24 | $336.8M | $566.7M |
净利润ASIXICUI
| Q4 25 | $-2.8M | $-15.7M | ||
| Q3 25 | $-2.6M | $-3.4M | ||
| Q2 25 | $31.4M | $35.3M | ||
| Q1 25 | $23.3M | $-15.5M | ||
| Q4 24 | $352.0K | $-23.8M | ||
| Q3 24 | $22.3M | $-33.0M | ||
| Q2 24 | $38.9M | $-21.4M | ||
| Q1 24 | $-17.4M | $-39.5M |
毛利率ASIXICUI
| Q4 25 | 7.6% | 37.5% | ||
| Q3 25 | 6.8% | 37.4% | ||
| Q2 25 | 14.3% | 37.9% | ||
| Q1 25 | 14.2% | 34.7% | ||
| Q4 24 | 3.4% | 36.1% | ||
| Q3 24 | 14.4% | 34.8% | ||
| Q2 24 | 17.9% | 34.8% | ||
| Q1 24 | 0.9% | 32.7% |
营业利润率ASIXICUI
| Q4 25 | -0.7% | 1.0% | ||
| Q3 25 | -0.9% | 2.6% | ||
| Q2 25 | 7.7% | 1.9% | ||
| Q1 25 | 7.7% | 2.1% | ||
| Q4 24 | -3.9% | 6.0% | ||
| Q3 24 | 7.5% | 1.4% | ||
| Q2 24 | 11.5% | 1.3% | ||
| Q1 24 | -7.0% | -1.9% |
净利率ASIXICUI
| Q4 25 | -0.8% | -2.9% | ||
| Q3 25 | -0.7% | -0.6% | ||
| Q2 25 | 7.7% | 6.4% | ||
| Q1 25 | 6.2% | -2.6% | ||
| Q4 24 | 0.1% | -3.8% | ||
| Q3 24 | 5.6% | -5.6% | ||
| Q2 24 | 8.6% | -3.6% | ||
| Q1 24 | -5.2% | -7.0% |
每股收益（稀释后）ASIXICUI
| Q4 25 | $-0.11 | $-0.63 | ||
| Q3 25 | $-0.10 | $-0.14 | ||
| Q2 25 | $1.15 | $1.43 | ||
| Q1 25 | $0.86 | $-0.63 | ||
| Q4 24 | $0.02 | $-0.97 | ||
| Q3 24 | $0.82 | $-1.35 | ||
| Q2 24 | $1.43 | $-0.88 | ||
| Q1 24 | $-0.65 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $2.1B |
| 总资产 | $1.7B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXICUI
| Q4 25 | $19.8M | — | ||
| Q3 25 | $23.7M | — | ||
| Q2 25 | $18.4M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | $19.6M | $308.6M | ||
| Q3 24 | $17.3M | $312.5M | ||
| Q2 24 | $12.1M | $302.6M | ||
| Q1 24 | $20.6M | $251.4M |
股东权益ASIXICUI
| Q4 25 | $815.2M | $2.1B | ||
| Q3 25 | $818.2M | $2.1B | ||
| Q2 25 | $823.7M | $2.1B | ||
| Q1 25 | $794.4M | $2.0B | ||
| Q4 24 | $774.6M | $2.0B | ||
| Q3 24 | $766.4M | $2.0B | ||
| Q2 24 | $746.6M | $2.0B | ||
| Q1 24 | $713.2M | $2.1B |
总资产ASIXICUI
| Q4 25 | $1.7B | $4.1B | ||
| Q3 25 | $1.7B | $4.1B | ||
| Q2 25 | $1.6B | $4.1B | ||
| Q1 25 | $1.6B | $4.2B | ||
| Q4 24 | $1.6B | $4.2B | ||
| Q3 24 | $1.5B | $4.3B | ||
| Q2 24 | $1.5B | $4.3B | ||
| Q1 24 | $1.5B | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $36.0M |
| 自由现金流率自由现金流/营收 | 10.0% | 6.6% |
| 资本支出强度资本支出/营收 | 7.7% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $91.8M |
8季度趋势，按日历期对齐
经营现金流ASIXICUI
| Q4 25 | $63.7M | $60.6M | ||
| Q3 25 | $26.6M | $56.7M | ||
| Q2 25 | $21.1M | $11.2M | ||
| Q1 25 | $11.4M | $51.3M | ||
| Q4 24 | $64.2M | $40.2M | ||
| Q3 24 | $57.3M | $36.1M | ||
| Q2 24 | $50.2M | $82.0M | ||
| Q1 24 | $-36.2M | $45.8M |
自由现金流ASIXICUI
| Q4 25 | $36.1M | $36.0M | ||
| Q3 25 | $66.0K | $27.6M | ||
| Q2 25 | $-7.2M | $-8.5M | ||
| Q1 25 | $-22.6M | $36.7M | ||
| Q4 24 | $29.8M | $16.1M | ||
| Q3 24 | $26.8M | $16.2M | ||
| Q2 24 | $16.7M | $62.5M | ||
| Q1 24 | $-71.6M | $29.9M |
自由现金流率ASIXICUI
| Q4 25 | 10.0% | 6.6% | ||
| Q3 25 | 0.0% | 5.1% | ||
| Q2 25 | -1.7% | -1.5% | ||
| Q1 25 | -6.0% | 6.1% | ||
| Q4 24 | 9.1% | 2.6% | ||
| Q3 24 | 6.7% | 2.7% | ||
| Q2 24 | 3.7% | 10.5% | ||
| Q1 24 | -21.3% | 5.3% |
资本支出强度ASIXICUI
| Q4 25 | 7.7% | 4.6% | ||
| Q3 25 | 7.1% | 5.4% | ||
| Q2 25 | 6.9% | 3.6% | ||
| Q1 25 | 9.0% | 2.4% | ||
| Q4 24 | 10.4% | 3.8% | ||
| Q3 24 | 7.7% | 3.4% | ||
| Q2 24 | 7.4% | 3.3% | ||
| Q1 24 | 10.5% | 2.8% |
现金转化率ASIXICUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | 0.32× | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
